05.08.2016 12:07:33
|
The Race To Cure Spinal Muscular Atrophy
(RTTNews) - What is life without a little fun, frolic and fooling around, especially for children? The essence of childhood is play, and there can be no greater misery than a child being robbed of this one heck of a source of joy. A dreaded genetic disorder called Spinal Muscular Atrophy, or SMA, that affects 1 in 10,000 children does just that, affecting the quality of life and in most cases proving fatal too.
SMA is the number 1 genetic cause of infant death. Based on the age of the initial onset of muscle weakness and severity of the disease, spinal muscular atrophy is classified into four types: Type I (Infantile), Type II (Intermediate), Type III (Juvenile) and Type IV (Adult onset).
Since this rare neuromuscular disease affects the nerve cells in the lower part of the brain and spinal cord that are responsible for neuro-muscular function, mobility becomes too difficult for children making them confined to a wheel chair. There is no treatment or cure yet for SMA. But there is hope at least for the future, as a few companies are working towards finding a treatment for Spinal Muscular Atrophy.
With August being observed as 'SMA awareness month', there could be no better time than now to take a look at some of the companies developing treatments for this inherited genetic muscle wasting disease.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Biogen Incmehr Nachrichten
20.01.25 |
NASDAQ Composite Index-Wert Biogen-Aktie: So viel Verlust hätte ein Biogen-Investment von vor 5 Jahren eingefahren (finanzen.at) | |
15.01.25 |
Freundlicher Handel: NASDAQ 100 präsentiert sich zum Ende des Mittwochshandels fester (finanzen.at) | |
14.01.25 |
NYSE-Handel: S&P 500 notiert zum Handelsende im Plus (finanzen.at) | |
14.01.25 |
NASDAQ 100 aktuell: NASDAQ 100 fällt letztendlich zurück (finanzen.at) | |
14.01.25 |
Gewinne in New York: NASDAQ 100 am Nachmittag im Aufwind (finanzen.at) | |
14.01.25 |
Anleger in New York halten sich zurück: So entwickelt sich der NASDAQ 100 am Mittag (finanzen.at) | |
14.01.25 |
NASDAQ-Handel: NASDAQ 100 zum Start des Dienstagshandels im Aufwind (finanzen.at) | |
13.01.25 |
NASDAQ Composite Index-Titel Biogen-Aktie: So viel Verlust hätte ein Investment in Biogen von vor 3 Jahren eingebracht (finanzen.at) |
Analysen zu Biogen Incmehr Analysen
Aktien in diesem Artikel
Biogen Inc | 136,75 | -0,04% | |
Ionis Pharmaceuticals Inc | 31,06 | -0,86% | |
Novartis AG (Spons. ADRS) | 95,20 | 0,63% | |
PTC Therapeutics Inc | 43,60 | 3,81% | |
Voyager Therapeutics Inc | 5,31 | 4,64% |